Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency (EXUROC)

18 november 2026 bijgewerkt door: Kristoffer Rohrberg

EXUROC Bladder Target - LP-184, an Acylfulvene, for PTGR1-positive, DNA Repair-deficient Urothelial Carcinoma. A Phase Ib/II Study of Safety, Tolerability, and Efficacy in Advanced/Metastatic Urothelial Carcinoma

This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma.

LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug.

The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics.

The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment.

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.

Studie Overzicht

Gedetailleerde beschrijving

EXUROC Bladder Target is an investigator-initiated, single-center, open-label, single-arm Phase Ib/II clinical trial evaluating the safety, tolerability, and antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma (UC) selected by PTGR1 positivity and DNA damage repair (DDR) deficiency.

LP-184 is a next-generation semisynthetic acylfulvene that acts as a prodrug requiring intracellular activation by prostaglandin reductase 1 (PTGR1). Following activation, LP-184 induces DNA damage that may be particularly cytotoxic to tumor cells with deficiencies in DNA repair pathways, including nucleotide excision repair (NER) and homologous recombination (HR). Preclinical studies have demonstrated enhanced sensitivity to acylfulvenes in tumors with impaired DNA repair mechanisms, providing the rationale for biomarker-based patient selection.

The study consists of two sequential phases:

Phase Ib: The first part will evaluate the safety and tolerability of LP-184 and determine the recommended Phase II dose (RP2D). A modified 3+3 dose de-escalation design will be applied, starting at 0.39 mg/kg, with predefined lower dose levels of 0.31 mg/kg and 0.25 mg/kg if dose-limiting toxicities (DLTs) occur. Safety and tolerability will be assessed, and dose de-escalation decisions will be based on observed toxicities.

Phase II: The second part will evaluate the antitumor activity of LP-184 at the RP2D using a Simon's two-stage minimax design. A total of 27 patients will contribute to the Phase II evaluation, including eligible patients treated during Phase Ib. The design allows for early termination if insufficient antitumor activity is observed during the first stage.

LP-184 will be administered intravenously on days 1 and 8 of each 21-day cycle. Treatment may continue for up to one year unless disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria occur.

Tumor response will be evaluated using RECIST version 1.1, and treatment-related adverse events will be assessed using CTCAE version 5.0. Quality of life will be assessed using the EORTC QLQ-C30 questionnaire.

The study aims to determine whether selecting patients based on PTGR1 expression and DDR deficiency can identify a population that may benefit from LP-184 treatment, potentially supporting further clinical development of this biomarker-driven therapeutic strategy.

Studietype

Ingrijpend

Inschrijving (Geschat)

39

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Copenhagen, Denemarken, 2100
        • Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, Denmark

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Provide signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses.
  • Histologically confirmed progressive, advanced (T4b, N+ or M1) urothelial carcinoma (UC)
  • Measurable disease by RECIST 1.1
  • DDR deficiency by local test
  • PTGR1 overexpression as defined by local test
  • ECOG performance status 0-1
  • Minimum age of 18 years
  • Life expectancy > 3 months
  • No prior treatment with acylfulvenes
  • At least one prior line of systemic treatment. Patients ineligible for standard second-line treatment may be considered for inclusion.
  • At least 4 weeks after major surgery or radiotherapy. Short-duration, limited-field radiotherapy for symptom control is allowed until 2 weeks before C1D1.
  • Adequate organ function at screening defined as:
  • Liver Function:

AST*, ALT* ≤3 × ULN or <5 × ULN in cases of documented liver metastases or involvement of the liver in the disease process.

Total serum bilirubin* ≤1.5 × ULN or <5 × ULN if secondary to Gilbert's Syndrome or documented liver metastases or involvement of the liver in the disease process.

•Renal Function: Serum creatinine clearance ≥45 mL/min either measured or calcu-lated using the standard Cockcroft-Gault formula.

•Bone Marrow Function:ANC* ≥1,5 × 10⁹/L. Hemoglobin* ≥5,0 mmol/L (The use of transfusion or other interven-tion to achieve hemoglobin ≥5,0 mmol/L is acceptable. For those pa-tients undergoing RBC transfusion, hemoglobin must be evaluated at least 14 days after the last RBC transfusion).

Platelet count* ≥100 × 10⁹/L (assessed ≥7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).

•Blood clotting function: INR* and aPTT* ≤1.5 × ULN. Patients on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for the intended use.

Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days of the first dose of LP-184. A woman is of child bearing potential unless she:

  • has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.
  • is aged ≥60 years and is amenorrhoeic.
  • is aged <60 years and has been amenorrhoeic for ≥12 months (including no irregular menses or spotting) in the absence of any medication which induces a meno-pausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone.

Women of childbearing potential must use highly effective contraception. Men of reproductive potential must agree to use highly effective contraceptive methods and avoid sperm donation during the study treatment and for 3 months after the last dose of LP-184. A man is of reproductive potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

Regarding brain metastases, based on one of the following:

  • No clinical evidence of brain metastases.
  • Previously treated brain metastases that are either stable for at least 4 weeks since last treatment or progressed since prior local CNS therapy and not requiring imme-diate re-treatment with local therapy.
  • Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible.

Exclusion Criteria:

  • Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives of the anti-cancer agent whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of LP-184. (Note: low-dose steroids (oral prednisone or equivalent ≤20 mg/day), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment.)

  • Any history of retinopathy and/or macular degeneration (without specifications or grades).

  • Infection requiring antibiotics, antivirals, or antifungals within 1 week prior to first dose of study drug. Prophylactic therapy for e.g. urinary tract infections allowed.

  • Hepatitis B and/or hepatitis C infection (determined on baseline hepatitis B and C screen) or known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).

  • Have clinically significant cardiac disease including:

    • New York Heart Association Class IV heart failure.
    • Myocardial infarction or stroke ≤3 months prior to the first dose of LP-184.
    • Unstable angina within ≤12 weeks prior to the first dose of LP-184 unless the underlying disease has been corrected by procedural intervention e.g., stent, bypass.
    • Severe aortic stenosis.
    • Uncontrolled arrhythmia.
    • QTc >470 milliseconds by Fridericia criteria.
    • Congenital long QT syndrome, or a QTcF interval >470 ms (average of triplicate ECGs) at screening and on Cycle 1 Day 1 (pre-dose) except for a documented bundle branch block or unless secondary to a pacemaker.
  • Have clinically significant AEs that have not resolved to baseline or ≤Grade 1 based on NCI-CTCAE prior to first dose of study drug, unless approved by the sponsor. Patients with chronic Grade 2 toxicities may be eligible at the discretion of the investigator, e.g. Grade 2 chemotherapy-induced neuropathy, alopecia, or hypothy-roidism from prior immunotherapy treatment).

  • Have any other serious medical condition which, in the opinion of the investigator, would preclude the patient from study participation.

  • Pregnant or breastfeeding women, or women of childbearing potential unwilling or unable to comply with contraception requirements.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: LP-184 arm

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. In Phase Ib, a modified 3+3 dose de-escalation design will be used to determine the recommended Phase II dose (RP2D). In Phase II, participants will receive LP-184 at the established RP2D.

LP-184 is an investigational semisynthetic acylfulvene administered intravenously on days 1 and 8 of each 21-day cycle. In Phase Ib, the starting dose is 0.39 mg/kg, with predefined dose de-escalation levels of 0.31 mg/kg and 0.25 mg/kg. In Phase II, LP-184 will be administered at the recommended Phase II dose (RP2D) established during Phase Ib. Treatment may continue for up to one year or until disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Dose-Limiting Toxicity
Tijdsspanne: During the first treatment cycle (21 days).

Number and proportion of participants experiencing dose-limiting toxicities (DLTs) associated with LP-184 treatment, assessed according to the protocol-defined DLT criteria and graded using CTCAE version 5.0.

During the first treatment cycle (21 days).
Recommended Phase II Dose (RP2D) of LP-184
Tijdsspanne: During Phase Ib dose evaluation, up to approximately 6 months

Determination of the recommended Phase II dose (RP2D) of LP-184 based on observed dose-limiting toxicities and overall safety and tolerability during Phase Ib.

During Phase Ib dose evaluation, up to approximately 6 months
Objective Response Rate (ORR) According to RECIST Version 1.1
Tijdsspanne: From treatment initiation until disease progression or end of treatment, up to 1 year.

Proportion of participants achieving a complete response (CR) or partial response (PR) as their best overall response, assessed according to RECIST version 1.1.

From treatment initiation until disease progression or end of treatment, up to 1 year.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-Free Survival (PFS)
Tijdsspanne: From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Time from initiation of LP-184 treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.
Overall Survival (OS)
Tijdsspanne: From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.

Time from initiation of LP-184 treatment to death from any cause.

From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.
Duration of Response (DoR)
Tijdsspanne: From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Time from the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, among participants achieving an objective response according to RECIST version 1.1.

From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

30 november 2026

Primaire voltooiing (Geschat)

1 november 2029

Studie voltooiing (Geschat)

1 november 2031

Studieregistratiedata

Eerst ingediend

3 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 november 2026

Eerst geplaatst (Werkelijk)

20 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

18 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data are not currently planned to be shared with external researchers.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren